Similar articles

• CD30+ lymphoproliferative disorders of the skin: still an open question.

  Alaibac M, Zarian H, Russo I, Peserico A. Alaibac M, et al. G Ital Dermatol Venereol. 2012 Dec;147(6):545-52. G Ital Dermatol Venereol. 2012. PMID: 23149700
• Acquired ichthyosis associated with primary cutaneous CD30+ lymphoproliferative disorders.

  López Aventín D, Gallardo F, Yébenes M, Lloreta J, Pujol RM. López Aventín D, et al. Eur J Dermatol. 2014 Jan-Feb;24(1):105-6. doi: 10.1684/ejd.2013.2225. Eur J Dermatol. 2014. PMID: 24491290 No abstract available.
• The role of p53 and anaplastic lymphoma kinase genes in the progression of cutaneous CD30(+) lymphoproliferative diseases.

  Kapur S, Tiemann M, Menke MA, Schubert C, Parwaresch R. Kapur S, et al. Indian J Med Res. 2005 Jan;121(1):46-54. Indian J Med Res. 2005. PMID: 15713979
• CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.

  Kempf W. Kempf W. J Cutan Pathol. 2006 Feb;33 Suppl 1:58-70. doi: 10.1111/j.0303-6987.2006.00548.x. J Cutan Pathol. 2006. PMID: 16412214 Review.
• Primary cutaneous CD30+ T-cell lymphoproliferative disorder following cardiac transplantation in a 15-year-old boy with Netherton's syndrome.

  Katugampola RP, Finlay AY, Harper JI, Dojcinov S, Maughan TS. Katugampola RP, et al. Br J Dermatol. 2005 Nov;153(5):1041-6. doi: 10.1111/j.1365-2133.2005.06839.x. Br J Dermatol. 2005. PMID: 16225622 Review.